SI0742013T1 - Stable liquid composition containing urate oxidase and lyophilized composition for its preparation - Google Patents

Stable liquid composition containing urate oxidase and lyophilized composition for its preparation

Info

Publication number
SI0742013T1
SI0742013T1 SI9630093T SI9630093T SI0742013T1 SI 0742013 T1 SI0742013 T1 SI 0742013T1 SI 9630093 T SI9630093 T SI 9630093T SI 9630093 T SI9630093 T SI 9630093T SI 0742013 T1 SI0742013 T1 SI 0742013T1
Authority
SI
Slovenia
Prior art keywords
urate oxidase
preparation
stable liquid
composition containing
liquid composition
Prior art date
Application number
SI9630093T
Other languages
English (en)
Slovenian (sl)
Inventor
Claude Aleman
Alain Bayol
Thierry Breul
Patrice Dupin
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of SI0742013T1 publication Critical patent/SI0742013T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI9630093T 1995-05-11 1996-05-09 Stable liquid composition containing urate oxidase and lyophilized composition for its preparation SI0742013T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9505606A FR2733914B1 (fr) 1995-05-11 1995-05-11 Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
EP96400995A EP0742013B1 (fr) 1995-05-11 1996-05-09 Composition liquide stable contenant de l'urate oxydase et composition lyophilisée pour sa préparation
US08/644,163 US5811096A (en) 1995-05-11 1996-05-10 Stable liquid composition containing urate oxidase and lyophilized composition for its preparation

Publications (1)

Publication Number Publication Date
SI0742013T1 true SI0742013T1 (en) 1999-12-31

Family

ID=26231954

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630093T SI0742013T1 (en) 1995-05-11 1996-05-09 Stable liquid composition containing urate oxidase and lyophilized composition for its preparation

Country Status (24)

Country Link
US (1) US5811096A (da)
EP (1) EP0742013B1 (da)
JP (1) JP2950775B2 (da)
CN (1) CN1090972C (da)
AT (1) ATE183925T1 (da)
AU (1) AU710288B2 (da)
BR (1) BR1100337A (da)
CA (1) CA2175971C (da)
CZ (1) CZ290799B6 (da)
DE (1) DE69604009T2 (da)
DK (1) DK0742013T3 (da)
EA (1) EA000024B1 (da)
ES (1) ES2137635T3 (da)
FR (1) FR2733914B1 (da)
GR (1) GR3031896T3 (da)
HU (1) HU225147B1 (da)
IL (1) IL118171A (da)
NO (1) NO315261B1 (da)
NZ (1) NZ286554A (da)
PL (1) PL184135B1 (da)
SG (1) SG42355A1 (da)
SI (1) SI0742013T1 (da)
TW (1) TW420614B (da)
ZA (1) ZA963683B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
DK1588716T3 (da) * 1998-08-06 2011-05-23 Mountain View Pharmaceuticals Peg-uratoxidase-konjugater og anvendelse deraf
FR2782455B3 (fr) * 1998-08-20 2000-09-15 Sanofi Sa Composition pharmaceutique injectable a base d'un sel pharmaceutiquement acceptable du clopidogrel ou de ticlopidine
AU2004216298B2 (en) * 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
PT1610822E (pt) * 2003-04-02 2011-01-05 Ares Trading Sa Formulações farmacêuticas líquidas ou liofilizadas de fsh e/ou lh em conjunto com o surfactante não iónico poloxâmero 188 e um agente bacteriostático
US7740884B2 (en) * 2003-06-20 2010-06-22 Ares Trading S.A. Freeze-dried FSH/LH formulations
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
SI3321359T1 (sl) 2005-04-11 2021-07-30 Horizon Pharma Rheumatology Llc Variantne oblike urat oksidaze in uporaba le-teh
BRPI0612942A2 (pt) 2005-04-11 2012-10-09 Savient Pharmaceuticals Inc forma variante de oxidase de urato e uso do mesmo
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
CN1864744B (zh) * 2005-05-18 2010-09-29 杭州北斗生物技术有限公司 含有尿酸氧化酶的药用制剂
WO2006125452A1 (en) * 2005-05-23 2006-11-30 Universite De Geneve Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
JP5033177B2 (ja) 2006-04-12 2012-09-26 サビエント ファーマセウティカルズ インク． 陽イオン界面活性剤によるタンパク質の精製
HUP1200205A3 (en) 2009-06-25 2012-09-28 Savient Pharmaceuticals Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
CN105412942B (zh) * 2015-12-23 2019-02-26 沈阳三生制药有限责任公司 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
JP2019511531A (ja) * 2016-04-13 2019-04-25 メディミューン，エルエルシー 高濃度のタンパク質ベース治療薬を含有する医薬組成物における安定化化合物としてのアミノ酸の使用
KR101744900B1 (ko) 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928137A (en) * 1971-10-20 1975-12-23 Mallinckrodt Inc Reagent formulation for uric acid assay
US3997470A (en) * 1971-10-20 1976-12-14 Mallinckrodt, Inc. Surfactant containing reagent formulations for assaying biological specimens and methods of preparing same
JPS51104807A (en) * 1975-03-12 1976-09-17 Hitachi Ltd Teepurekoodano ootoribaasuseigyokairo
JPS5417027A (en) * 1977-07-07 1979-02-08 Canon Inc Image forming system
DE3126759A1 (de) * 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
JPS60224499A (ja) * 1984-04-23 1985-11-08 Toyobo Co Ltd 安定なウリカ−ゼ製剤
DE3743405A1 (de) * 1987-05-14 1988-11-24 Boehringer Mannheim Gmbh Verfahren zur bestimmung von fructosamin
JPH0243471A (ja) * 1988-08-03 1990-02-14 Iwataro Moriyama 立体駐車装置

Also Published As

Publication number Publication date
TW420614B (en) 2001-02-01
CA2175971C (en) 2003-12-30
AU5213996A (en) 1996-11-21
DE69604009D1 (de) 1999-10-07
EA000024B1 (ru) 1997-12-30
HUP9601241A2 (en) 1997-04-28
DE69604009T2 (de) 2000-04-06
JP2950775B2 (ja) 1999-09-20
PL314147A1 (en) 1996-11-12
NZ286554A (en) 1998-09-24
GR3031896T3 (en) 2000-02-29
NO961915L (no) 1996-11-12
FR2733914B1 (fr) 1997-08-01
HUP9601241A3 (en) 2000-06-28
EP0742013A1 (fr) 1996-11-13
HU9601241D0 (en) 1996-07-29
FR2733914A1 (fr) 1996-11-15
EP0742013B1 (fr) 1999-09-01
PL184135B1 (pl) 2002-09-30
BR1100337A (pt) 2000-07-25
MX9601756A (es) 1997-07-31
SG42355A1 (en) 1997-08-15
US5811096A (en) 1998-09-22
EA199600024A2 (ru) 1996-12-30
CZ290799B6 (cs) 2002-10-16
ZA963683B (en) 1997-11-10
ES2137635T3 (es) 1999-12-16
JPH0925242A (ja) 1997-01-28
HU225147B1 (en) 2006-07-28
EA199600024A3 (ru) 1997-03-31
NO315261B1 (no) 2003-08-11
DK0742013T3 (da) 2000-03-06
CN1147961A (zh) 1997-04-23
NO961915D0 (no) 1996-05-10
IL118171A (en) 2000-08-31
CZ135096A3 (en) 1996-12-11
IL118171A0 (en) 1996-09-12
ATE183925T1 (de) 1999-09-15
CA2175971A1 (en) 1996-11-12
CN1090972C (zh) 2002-09-18
AU710288B2 (en) 1999-09-16

Similar Documents

Publication Publication Date Title
GR3031896T3 (en) Stable liquid composition containing urate oxidase and lyophilized composition for its preparation
GR3034191T3 (en) Formulations for lipophilic compounds
AU7549696A (en) Bioadhesive pharmaceutical composition for the controlled release of active principles
LU92615I2 (fr) Alogliptin et ses dérivés pharmaceutiquement acceptables (VIPIDIA)
AU1777495A (en) Stable freeze-dried formulation comprising a protein; assay kit
GR3033204T3 (en) Formulations of blood clot-polymer matrix for delivery of osteogenic proteins.
CA2258095A1 (en) Tetrahydrolipstatin containing compositions
ZA895936B (en) Pharmaceutical compositions comprising selected lactobacillus strains
EP1013274A3 (en) Composition comprising amoxycillin and clavulanic acid
AU647933B2 (en) Megestrol acetate formulation
CA2294448A1 (en) Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins
ITMI911580A1 (it) Preparazioni oftalmiche a rilascio protratto
CA2125643A1 (en) Pharmaceutical composition having analgesic activity
CA2103725A1 (en) Composition for use in transdermal administration
HK1036413A1 (en) Solution comprising prostaglandins and benzyl alcohol.
CA2220103A1 (en) Composition comprising amoxycillin and clavulanic acid
MX9708383A (es) Composicion que comprende amoxicilina y acido clavulanico.
AU2458492A (en) Medicaments for treating gastrointestinal disorders

Legal Events

Date Code Title Description
SP73 Change of data on owner

Owner name: SANOFI-AVENTIS; FR

Effective date: 20050204